In Bloomberg Law, Health Care Partner Discusses Legal Challenges Facing Trump Administration’s International Drug Pricing Plan

In The News
July 15, 2019
Thomas N. Bulleit
Capital Insights.

Health care partner Tom Bulleit (Washington, D.C.) was quoted in an article published July 15 by Bloomberg Law that examines the Trump administration’s international drug pricing plan.

Mr. Bulleit explains that the International Pricing Index policy could face challenges in court similar to the Trump administration’s most recent initiative to put prices of drugs in advertisements. He notes that lawsuits may claim the proposed IPI policy, which would affect tens of millions of Medicare beneficiaries, exceeds the government’s authority, arguing Congress needs to step in to change the drug payment formula.


Thomas N. Bulleit
Thomas N. Bulleit
Retired Partner